Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jul;60(1):9–11. doi: 10.1038/bjc.1989.209

Chemotherapy of non-small cell lung cancer.

C J Williams 1
PMCID: PMC2247340  PMID: 2553089

Full text

PDF
9

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cullen M. H., Joshi R., Chetiyawardana A. D., Woodroffe C. M. Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer. 1988 Sep;58(3):359–361. doi: 10.1038/bjc.1988.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gralla R. J., Casper E. S., Kelsen D. P., Braun D. W., Jr, Dukeman M. E., Martini N., Young C. W., Golbey R. B. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med. 1981 Oct;95(4):414–420. doi: 10.7326/0003-4819-95-4-414. [DOI] [PubMed] [Google Scholar]
  3. Holmes E. C., Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol. 1986 May;4(5):710–715. doi: 10.1200/JCO.1986.4.5.710. [DOI] [PubMed] [Google Scholar]
  4. Mackillop W. J., Ward G. K., O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer. 1986 Oct;54(4):661–667. doi: 10.1038/bjc.1986.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Mountain C. F. A new international staging system for lung cancer. Chest. 1986 Apr;89(4 Suppl):225S–233S. doi: 10.1378/chest.89.4_supplement.225s. [DOI] [PubMed] [Google Scholar]
  6. Rapp E., Pater J. L., Willan A., Cormier Y., Murray N., Evans W. K., Hodson D. I., Clark D. A., Feld R., Arnold A. M. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633–641. doi: 10.1200/JCO.1988.6.4.633. [DOI] [PubMed] [Google Scholar]
  7. Shields T. W., Higgins G. A., Jr, Humphrey E. W., Matthews M. J., Keehn R. J. Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer. 1982 Nov 1;50(9):1713–1721. doi: 10.1002/1097-0142(19821101)50:9<1713::aid-cncr2820500910>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  8. Shields T. W., Robinette C. D., Keehn R. J. Bronchial carcinoma treated by adjuvant cancer chemotherapy. Arch Surg. 1974 Aug;109(2):329–333. doi: 10.1001/archsurg.1974.01360020189037. [DOI] [PubMed] [Google Scholar]
  9. Simes R. J. Risk-benefit relationships in cancer clinical trials: the ECOG experience in non-small-cell lung cancer. J Clin Oncol. 1985 Apr;3(4):462–472. doi: 10.1200/JCO.1985.3.4.462. [DOI] [PubMed] [Google Scholar]
  10. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group. J Clin Oncol. 1988 Jan;6(1):9–17. doi: 10.1200/JCO.1988.6.1.9. [DOI] [PubMed] [Google Scholar]
  11. Van Houtte P., Rocmans P., Smets P., Goffin J. C., Lustman-Maréchal J., Vanderhoeft P., Henry J. Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys. 1980 Aug;6(8):983–986. doi: 10.1016/0360-3016(80)90105-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES